A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

This randomized phase III trial studies two different schedules of zoledronic acid to compare
how well they work in reducing bone-related complications in patients with breast cancer,
prostate cancer, or multiple myeloma that has spread to other places in the body and have
bone involvement. Bone-related complications are a major cause of morbidity in patients with
metastatic prostate cancer, breast cancer, and multiple myeloma. Zoledronic acid may stop the
growth of cancer cells in the bone and may help relieve some of the symptoms caused by bone
metastases. It is not yet known whether giving zoledronic acid more or less frequently is
more effective in treating patients with metastatic cancer that has spread to the bone.